Markets:

Overview

News

Currencies

International

Treasuries

Morgan Stanley (NY:MS)

196.31 -0.01 (-0.01%)

Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Morgan Stanley

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Morgan Stanley Investment Management Closes Inaugural Growth Equity Investment Fund Oversubscribed at $1.3 Billion

September 16, 2026

From Morgan Stanley Investment Management

Via Business Wire

S&P 500 Trucking Stock Craters On CFO's Warning ↗

September 16, 2026

J.B. Hunt warned of lower Q3 earnings amid surging fuel costs and higher yields.

Via Investor's Business Daily

Topics Stocks

Morgan Stanley Investment Management Announces Effort to Convert Nearly $10 Billion in Municipal Mutual Funds to ETFs

September 16, 2026

From Morgan Stanley Investment Management

Via Business Wire

GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline ↗

September 16, 2026

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of...

Via MarketBeat

Topics Intellectual Property

One Wall Street Analyst Just Said Tesla Stock Could Be Worth $840: Time to Buy? ↗

September 16, 2026

The analyst update is not particularly significant on its own, but it helps highlight a Tesla business that deserves more attention.

Via The Motley Fool

Morgan Stanley Sees Wealth, AI Financing and Deal Rebound Powering Growth ↗

September 16, 2026

Morgan Stanley (NYSE:MS) Co-President Dan Simkowitz said the firm does not view 2026 as a peak-earnings year, citing growth opportunities in wealth management, a developing capital-markets recovery and...

Via MarketBeat

Topics Artificial Intelligence

Honeywell Sees Strong Start as Pure-Play Automation Push Gains Momentum ↗

September 16, 2026

Honeywell International (NASDAQ:HON) Chairman and CEO Vimal Kapur said the company is seeing stronger-than-expected early-quarter momentum as it begins operating as a more focused automation business...

Via MarketBeat

Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities ↗

September 16, 2026

Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas...

Via MarketBeat

Topics ETFs

Rivian Calls R2 Launch an Inflection Point as Demand, Autonomy Plans Accelerate ↗

September 15, 2026

Rivian Automotive (NASDAQ:RIVN) is entering what founder and CEO RJ Scaringe described as an “inflection point year,” as the electric-vehicle maker begins scaling its R2 midsize SUV and expands its...

Via MarketBeat

Topics Supply Chain

RTX Highlights $289B Backlog as Aerospace, Defense Demand Powers Growth ↗

September 15, 2026

RTX (NYSE:RTX) Chairman, President and CEO Chris Calio said the aerospace and defense company remains positioned to benefit from sustained commercial aviation and defense demand, citing a $289 billion...

Via MarketBeat

Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth ↗

September 15, 2026

Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are...

Via MarketBeat

Topics Artificial Intelligence

General Motors Sees Q3 on Track as Truck Launch, Digital Growth Fuel 2027 Outlook ↗

September 15, 2026

General Motors (NYSE:GM) Chief Financial Officer Paul Jacobson said the automaker’s business is tracking consistently with its expectations for the third quarter, supported by resilient consumer...

Via MarketBeat

Topics Economy World Trade

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗

September 15, 2026

Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief...

Via MarketBeat

Topics Intellectual Property

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline ↗

September 15, 2026

AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s...

Via MarketBeat

Topics ETFs

Stocks making big moves yesterday: Corning, Baldwin Insurance Group, Gartner, Jabil, and Accenture

September 15, 2026

Check out the companies making headlines yesterday: Corning (NYSE:GLW): Glass and electronic component manufacturer Corning (NYSE:GLW) fell by 12.7% on Monda...

Via StockStory

Topics Artificial Intelligence

Wall Street Sells the AI-Pause Weekend as Brent Punches Through $106 and the Ten-Year Cracks 5% for the First Time Since 2023 ↗

September 15, 2026

Via Chartmill

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗

September 15, 2026

Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic...

Via MarketBeat

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley...

Via MarketBeat

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗

September 14, 2026

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13...

Via MarketBeat

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗

September 14, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...

Via MarketBeat

Topics Intellectual Property

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded...

Via MarketBeat

Topics World Trade

CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗

September 14, 2026

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected...

Via MarketBeat

Topics Intellectual Property

Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation ↗

September 14, 2026

Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its...

Via MarketBeat

Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗

September 14, 2026

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing...

Via MarketBeat

Why Accenture (ACN) Stock Is Up Today

September 14, 2026

What Happened? Shares of global professional services company Accenture (NYSE:ACN) jumped 5.2% in the afternoon session after Morgan Stanley raised its price...

Via StockStory

Topics Artificial Intelligence

Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition ↗

September 14, 2026

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline...

Via MarketBeat

Topics ETFs Economy

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗

September 14, 2026

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining...

Via MarketBeat

Topics Intellectual Property World Trade

Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types ↗

September 14, 2026

Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma...

Via MarketBeat

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...

Via MarketBeat

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal ↗

September 14, 2026

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology &...

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.